Open-label Long-Term Extension Study for Participants With Treatment-Resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment From Study 54135419TRD3013
Latest Information Update: 15 Jan 2025
At a glance
- Drugs Esketamine (Primary) ; Neurotransmitter uptake inhibitors; Serotonin uptake inhibitors
- Indications Major depressive disorder
- Focus Adverse reactions; Therapeutic Use
- Acronyms ESCAPE-LTE
- Sponsors Janssen-Cilag
Most Recent Events
- 15 Aug 2024 Status changed from active, no longer recruiting to completed.
- 03 Jul 2024 This trial has been completed in Bulgaria, according to European Clinical Trials Database record.
- 08 May 2024 This trial has been completed in Finland , according to European Clinical Trials Database record.